BIOLOGICAL · Unmapped registry intervention
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Find medicine records ·
Find other trials using this name
Clinical trial
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
NCT02157051
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
OTHER · Unmapped registry intervention
Laboratory Biomarker Analysis
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedVaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE1
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
HER2 Negative Breast Carcinomaunresolved
Recurrent Breast Carcinomaunresolved
Stage IIIA Breast Cancerunresolved
Stage IIIB Breast Cancerunresolved
Stage IIIC Breast Cancerunresolved
Stage IV Breast Cancerunresolved
Stage III Breast Cancerunresolved
Interventions
Sponsors & collaborators
University of Washingtonlead sponsor
United States Department of Defensecollaborator
Breast Cancer Alliancecollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02157051 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.